DK141172B - Fremgangsmåde til fremstilling af virusproteiner af influenzavirus. - Google Patents

Fremgangsmåde til fremstilling af virusproteiner af influenzavirus. Download PDF

Info

Publication number: DK141172B
Authority: DK; Denmark
Prior art keywords: neuraminidase; hemagglutinin; virus; influenza virus; suspension
Prior art date: 1974-03-05

Application number

DK85775AA

Other languages

Danish (da)

English (en)

Other versions

DK141172C (fr

DK85775A (fr

Inventor

Robert Fontanges

Original Assignee

Science Union & Cie

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1974-03-05

Filing date

1975-03-04

Publication date

1980-01-28

1975-03-04 Application filed by Science Union & Cie filed Critical Science Union & Cie

1975-11-03 Publication of DK85775A publication Critical patent/DK85775A/da

1980-01-28 Publication of DK141172B publication Critical patent/DK141172B/da

1980-07-14 Application granted granted Critical

1980-07-14 Publication of DK141172C publication Critical patent/DK141172C/da

Links

238000000034 method Methods 0.000 title description 12
241000712461 unidentified influenza virus Species 0.000 title description 11
108010067390 Viral Proteins Proteins 0.000 title 1
102000005348 Neuraminidase Human genes 0.000 description 33
108010006232 Neuraminidase Proteins 0.000 description 33
101710154606 Hemagglutinin Proteins 0.000 description 27
101710093908 Outer capsid protein VP4 Proteins 0.000 description 27
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 27
101710176177 Protein A56 Proteins 0.000 description 27
239000000185 hemagglutinin Substances 0.000 description 27
241000700605 Viruses Species 0.000 description 21
239000000725 suspension Substances 0.000 description 13
108090000288 Glycoproteins Proteins 0.000 description 11
102000003886 Glycoproteins Human genes 0.000 description 11
230000000694 effects Effects 0.000 description 11
239000000243 solution Substances 0.000 description 10
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
229940088598 enzyme Drugs 0.000 description 8
239000000203 mixture Substances 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
108091005804 Peptidases Proteins 0.000 description 6
239000004365 Protease Substances 0.000 description 6
241000187438 Streptomyces fradiae Species 0.000 description 5
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 5
PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 5
235000013923 monosodium glutamate Nutrition 0.000 description 5
229940073490 sodium glutamate Drugs 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 4
230000009471 action Effects 0.000 description 4
230000000890 antigenic effect Effects 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
238000011026 diafiltration Methods 0.000 description 4
238000001962 electrophoresis Methods 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
230000008569 process Effects 0.000 description 4
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 4
BCMWYYCCTCFRMH-UHFFFAOYSA-M sodium;4-dodecoxy-4-oxobutanoate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CCC([O-])=O BCMWYYCCTCFRMH-UHFFFAOYSA-M 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
108010004032 Bromelains Proteins 0.000 description 3
241000287828 Gallus gallus Species 0.000 description 3
102000035195 Peptidases Human genes 0.000 description 3
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
239000003599 detergent Substances 0.000 description 3
235000013601 eggs Nutrition 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
239000012530 fluid Substances 0.000 description 3
206010022000 influenza Diseases 0.000 description 3
239000000463 material Substances 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
235000019419 proteases Nutrition 0.000 description 3
238000000926 separation method Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000013543 active substance Substances 0.000 description 2
210000001643 allantois Anatomy 0.000 description 2
235000019835 bromelain Nutrition 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
125000002091 cationic group Chemical group 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000002329 infrared spectrum Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
HKJKONMZMPUGHJ-UHFFFAOYSA-N 4-amino-5-hydroxy-3-[(4-nitrophenyl)diazenyl]-6-phenyldiazenylnaphthalene-2,7-disulfonic acid Chemical compound OS(=O)(=O)C1=CC2=CC(S(O)(=O)=O)=C(N=NC=3C=CC=CC=3)C(O)=C2C(N)=C1N=NC1=CC=C([N+]([O-])=O)C=C1 HKJKONMZMPUGHJ-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
101000613243 Gadus morhua Trypsin-10 Proteins 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
241001500350 Influenzavirus B Species 0.000 description 1
102000001621 Mucoproteins Human genes 0.000 description 1
108010093825 Mucoproteins Proteins 0.000 description 1
SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
108010059712 Pronase Proteins 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108010003533 Viral Envelope Proteins Proteins 0.000 description 1
239000002253 acid Substances 0.000 description 1
108010027597 alpha-chymotrypsin Proteins 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
229960002319 barbital Drugs 0.000 description 1
FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000012535 impurity Substances 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
-1 nicotinyl dodecyl Chemical group 0.000 description 1
239000008055 phosphate buffer solution Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000000047 product Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
239000013049 sediment Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
OTNVGWMVOULBFZ-UHFFFAOYSA-N sodium;hydrochloride Chemical compound [Na].Cl OTNVGWMVOULBFZ-UHFFFAOYSA-N 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
108010050327 trypticase-soy broth Proteins 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Virology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

DK85775AA 1974-03-05 1975-03-04 Fremgangsmåde til fremstilling af virusproteiner af influenzavirus. DK141172B (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR7407352A FR2262962B1 (fr)	1974-03-05	1974-03-05
FR7407352		1974-03-05

Publications (3)

Publication Number	Publication Date
DK85775A DK85775A (fr)	1975-11-03
DK141172B true DK141172B (da)	1980-01-28
DK141172C DK141172C (fr)	1980-07-14

Family

ID=9135822

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK85775AA DK141172B (da)	1974-03-05	1975-03-04	Fremgangsmåde til fremstilling af virusproteiner af influenzavirus.

Country Status (12)

Country	Link
US (1)	US4136168A (fr)
JP (1)	JPS50160487A (fr)
BE (1)	BE826275A (fr)
CA (1)	CA1052306A (fr)
CH (1)	CH595106A5 (fr)
DE (1)	DE2508396A1 (fr)
DK (1)	DK141172B (fr)
ES (1)	ES435323A1 (fr)
FR (1)	FR2262962B1 (fr)
GB (1)	GB1469901A (fr)
NL (1)	NL7502623A (fr)
ZA (1)	ZA751357B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI790483A7 (fi) *	1978-02-16	1979-08-17	Science Union & Cie	Foerfarande foer framstaellning av ett enzym av bakteriellt ursprung och farmaceutiska kompositioner innehaollande detsamma
CA1122527A (fr) *	1979-05-15	1982-04-27	Karen K. Brown	Production d'un vaccin contre l'influenza par culture de cellules en milieu liquide
US4365187A (en) *	1980-05-15	1982-12-21	Rotron Incorporated	Brushless D.C. motor
US4537769A (en) *	1982-04-06	1985-08-27	American Cyanamid Company	Stabilization of influenza virus vaccine
JPS59163313A (ja) *	1983-03-09	1984-09-14	Teijin Ltd	経鼻投与用ペプチドホルモン類組成物
US6398774B1 (en)	1999-09-29	2002-06-04	Heska Corporation	Intranasal delivery system
US7678087B2 (en) *	1999-09-29	2010-03-16	Heska Corporation	Equine intranasal delivery system

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4029763A (en) *	1974-08-05	1977-06-14	Mount Sinai School Of Medicine Of The City University Of New York	Influenza vaccine containing purified neuraminidase antigen and method of using the same

1974
- 1974-03-05 FR FR7407352A patent/FR2262962B1/fr not_active Expired
1975
- 1975-02-26 DE DE19752508396 patent/DE2508396A1/de not_active Withdrawn
- 1975-02-26 US US05/553,293 patent/US4136168A/en not_active Expired - Lifetime
- 1975-03-03 GB GB874375A patent/GB1469901A/en not_active Expired
- 1975-03-04 JP JP50026445A patent/JPS50160487A/ja active Pending
- 1975-03-04 DK DK85775AA patent/DK141172B/da unknown
- 1975-03-04 BE BE153990A patent/BE826275A/fr unknown
- 1975-03-04 CA CA221,238A patent/CA1052306A/fr not_active Expired
- 1975-03-05 NL NL7502623A patent/NL7502623A/xx not_active Application Discontinuation
- 1975-03-05 ES ES435323A patent/ES435323A1/es not_active Expired
- 1975-03-05 CH CH279375A patent/CH595106A5/xx not_active IP Right Cessation
- 1975-03-05 ZA ZA00751357A patent/ZA751357B/xx unknown

Also Published As

Publication number	Publication date
GB1469901A (en)	1977-04-06
ZA751357B (en)	1976-02-25
BE826275A (fr)	1975-09-04
DK141172C (fr)	1980-07-14
FR2262962B1 (fr)	1977-11-04
ES435323A1 (es)	1976-12-16
DK85775A (fr)	1975-11-03
DE2508396A1 (de)	1975-10-23
US4136168A (en)	1979-01-23
CH595106A5 (fr)	1978-01-31
CA1052306A (fr)	1979-04-10
FR2262962A1 (fr)	1975-10-03
NL7502623A (nl)	1975-09-09
JPS50160487A (fr)	1975-12-25
AU7878175A (en)	1976-09-09

Publication	Publication Date	Title
Lazarowitz et al.	1975	Enhancement of the infectivity of influenza A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide
KR101190932B1 (ko)	2012-10-16	인플루엔자 백신 조성물의 제조 방법
Chen et al.	2001	A novel influenza A virus mitochondrial protein that induces cell death
US8497112B2 (en)	2013-07-30	Method for producing viral vaccines
Kaverin et al.	1995	Impairment of multicycle influenza virus growth in Vero (WHO) cells by loss of trypsin activity
Opitz et al.	2007	Lectin-affinity chromatography for downstream processing of MDCK cell culture derived human influenza A viruses
Buffin et al.	2019	Influenza A and B virus-like particles produced in mammalian cells are highly immunogenic and induce functional antibodies
US8173021B2 (en)	2012-05-08	Method for the preparation of sulfated cellulose membranes and sulfated cellulose membranes
Kendal	1975	A comparison of “influenza C” with prototype myxoviruses: Receptor-destroying activity (neuraminidase) and structural polypeptides
EP3027640B1 (fr)	2018-03-07	Protéines d'hémagglutinine de la grippe et méthodes associées
Kohama et al.	1981	Changes in conformation and charge paralleling proteolytic activation of Newcastle disease virus glycoproteins
Weigel et al.	2016	A membrane-based purification process for cell culture-derived influenza A virus
EP1725581B1 (fr)	2008-08-06	Nouveau dosage pour separer et quantifier des antigenes d'hemagglutinine
Fortuna et al.	2019	Use of sulfated cellulose membrane adsorbers for chromatographic purification of cell cultured-derived influenza A and B viruses
Bissinger et al.	2021	Towards integrated production of an influenza A vaccine candidate with MDCK suspension cells
Jing et al.	2012	Increased hemagglutinin content in a reassortant 2009 pandemic H1N1 influenza virus with chimeric neuraminidase containing donor A/Puerto Rico/8/34 virus transmembrane and stalk domains
Michalski et al.	2000	The cleavage activation and sites of glycosylation in the fusion protein of Hendra virus
Holland	1961	The purification and properties of megacin, a bacteriocin from Bacillus megaterium
US11999975B2 (en)	2024-06-04	Method for purifying an enveloped virus
SUPERTT et al.	1981	Receptors for BK virus on human erythrocytes
JPH11509081A (ja)	1999-08-17	新規の複製プロセス
Li et al.	1980	Protein organization in Newcastle disease virus as revealed by perturbant treatment
US4195076A (en)	1980-03-25	Process for the preparation of hemagglutinin from viral sources and methods of utilizing same
US4136168A (en)	1979-01-23	Process for the preparation of neuraminidase from viral sources and methods of utilizing same
Leavitt et al.	1979	Human influenza A virus: comparative analysis of the structural polypeptides by two-dimensional polyacrylamide gel electrophoresis